GlassScriptPhysician profile
Michael S Dent
NPI 1881821585
$2,810.57
in general payments reported to CMS, 2019-2025
25 companies · $948 in 2025
The $948 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $131 · 2021: $162 · 2022: $630 · 2023: $460 · 2024: $382 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.84 | 2021-2025 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $296.71 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $241.55 | 2022-2025 | |
| Galderma Laboratories, L.P. | $197.96 | 2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $191.02 | 2022-2025 | |
| Dermavant Sciences, INC. | $181.08 | 2023-2024 | Vtama |
| Lilly USA, LLC | $161.66 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $137.06 | 2020-2025 | Otezla, Otezla |
| Journey Medical Corporation | $116.67 | 2020 | |
| Stemline Therapeutics INC. | $112.48 | 2022 | |
| Allergan, INC. | $97.33 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.42 | 2022-2024 | Siliq |
| Organogenesis INC. | $67.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.26 | 2024 | Spevigo |
| Leo Pharma INC. | $63.02 | 2023-2025 | Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $61.06 | 2022-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $55.55 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.01 | 2025 | Sotyktu |
| Incyte Corporation | $39.97 | 2024-2025 | Opzelura |
| Genzyme Corporation | $39.34 | 2022-2025 | |
| Almirall LLC | $26.18 | 2025 | Klisyri |
| Genentech USA, INC. | $18.00 | 2021 | |
| Botanix Sb INC | $16.27 | 2025 | Sofdra |
| Ucb, INC. | $14.05 | 2025 | Bimzelx |
| Biofrontera INC. | $9.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.